Scholar Rock (NASDAQ:SRRK) Insider Sells $399,341.88 in Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) insider Mo Qatanani sold 8,484 shares of the company’s stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $47.07, for a total value of $399,341.88. Following the sale, the insider owned 98,445 shares of the company’s stock, valued at approximately $4,633,806.15. This trade represents a 7.93% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Mo Qatanani also recently made the following trade(s):

• On Tuesday, February 17th, Mo Qatanani sold 7,989 shares of Scholar Rock stock. The shares were sold at an average price of $46.53, for a total value of $371,728.17.
• On Thursday, January 22nd, Mo Qatanani sold 14,898 shares of Scholar Rock stock. The shares were sold at an average price of $46.71, for a total value of $695,885.58.
• On Friday, January 16th, Mo Qatanani sold 8,406 shares of Scholar Rock stock. The stock was sold at an average price of $44.48, for a total transaction of $373,898.88.
• On Wednesday, January 14th, Mo Qatanani sold 13,112 shares of Scholar Rock stock. The stock was sold at an average price of $45.20, for a total transaction of $592,662.40.
• On Thursday, December 4th, Mo Qatanani sold 136,462 shares of Scholar Rock stock. The stock was sold at an average price of $45.21, for a total transaction of $6,169,447.02.

Scholar Rock Stock Performance

Shares of NASDAQ:SRRK traded down $0.05 during midday trading on Wednesday, hitting $46.97. The company had a trading volume of 474,449 shares, compared to its average volume of 974,988. The company has a fifty day moving average of $45.25 and a two-hundred day moving average of $38.63. Scholar Rock Holding Corporation has a 12-month low of $22.71 and a 12-month high of $49.82. The company has a debt-to-equity ratio of 0.41, a current ratio of 6.30 and a quick ratio of 6.30. The company has a market cap of $4.79 billion, a price-to-earnings ratio of -14.91 and a beta of 0.67.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. IFP Advisors Inc raised its stake in Scholar Rock by 294.1% during the fourth quarter. IFP Advisors Inc now owns 603 shares of the company’s stock valued at $27,000 after purchasing an additional 450 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in shares of Scholar Rock in the 4th quarter worth approximately $30,000. Summit Securities Group LLC purchased a new stake in Scholar Rock during the 4th quarter valued at $31,000. EverSource Wealth Advisors LLC increased its position in Scholar Rock by 151.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock valued at $38,000 after acquiring an additional 525 shares during the last quarter. Finally, Hilton Head Capital Partners LLC bought a new stake in shares of Scholar Rock in the 4th quarter worth about $44,000. 91.08% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on SRRK. BMO Capital Markets reaffirmed an “outperform” rating and issued a $50.00 price objective on shares of Scholar Rock in a research note on Friday, November 14th. UBS Group began coverage on Scholar Rock in a report on Wednesday, January 7th. They issued a “buy” rating and a $60.00 price target on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Scholar Rock in a report on Thursday, December 11th. Wolfe Research began coverage on shares of Scholar Rock in a report on Tuesday, November 18th. They issued an “outperform” rating and a $42.00 target price on the stock. Finally, Barclays upped their target price on shares of Scholar Rock from $45.00 to $52.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 17th. Four research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $51.14.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).